Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Stem Cell Mobilization Regimens in Multiple Myeloma
NCT01146834Phase 3Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2011
- Primary completion
- Feb 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (5 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Percentage of patients able to collect >6 x 10^6 CD34+ cells/kg in < 2 collections at 36 months. Started Mar 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01146834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146834.